Efficacy of teicoplanin, administered in two different regimens, in the treatment of experimental endocarditis due to Enterococcus faecalis

Journal of Chemotherapy

Volumn 20, Issue 2, 2008, Pages 208-212

  Pavleas, John ^a   Skiada, A ^b   Daikos, G L ^b   Pefanis, A ^b   Giamarellos Bourboulis, E ^b   Kanellakopoulou, K ^b   Tsaganos, T ^b   Perrea, D ^b   Donta, I ^b   Karayannakos, P ^b   Giamarellou, H ^b  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Enterococcus; Experimental endocarditis; Teicoplanin

Indexed keywords

AMPICILLIN; GENTAMICIN; TEICOPLANIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL SURVIVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RABBIT; RECURRENT DISEASE;

EID: 44849102798     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.2.208     Document Type: Article

References (32)

1. Grayson ML, Eliopoulos GM, Wennersten CB, Ruoff KL, De Girolami PC, Ferraro MJ, Moellering RC Jr. Increasing resistance to β-lactam antibiotic among isolates of Enterococcus faecium: A 22-year review at one institution. Antimicrob Agents Chemother 1991;35:2180-2184.
2. Murray BE. The life and times of enterococcus. Clin Microbiol Rev 1990;3:46-65.
3. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991;91, Suppl.3B, 72S-75S.
4. Mylonakis EL, Calderwood SB. Infective endocarditis in adults. NEJM 2001;345:1318-1330.
5. Megran DW. Diagnosis and treatment of enterococcal endocarditis. Hosp Pract 1993;15:41-50.
6. Le T, Bayer SA. Combination antibiotic therapy for infective endocarditis. Clin Infect Dis 2003;36:615-621.
7. Elliott TSJ, Foweraker J, Gould FK, Perry JD, Sandoe JAT. Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2004;54:971-981.
8. Sullam P, Tauber M, Hackbarth C, Sande MA. Therapeutic efficacy of teicoplanin in experimental enterococcal endocarditis. Antimicrob Agents Chemother. 1985;27:135-136
9. Fantin B, Leclercq R, Arthur M, Duval J, Carbon C. Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium. Antimicrob Agents Chemother 1991;35:1570-1575.
10. Caron F, Kitzis M, Gutman L, Cremieux AC, Maziere B, Vallois JM, et al. Daptomycin or teicoplanin with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother. 1992;36:2611-2616.
11. Lopez P, Gavalda J, Martin MT, Almirante B, Gomis X, Azuaje C, et al. Efficacy of teicoplanin-gentamicin given once a day on the basis of pharmacokinetics in humans for treatment of enterococcal experimental endocarditis. Antimicrob Agents Chemother 2001;45:1387-1393.
12. Gutierrez J, Hoyos A, Piedrola G. Synergy between aminoglycosides and penicillin, teicoplanin and cefpirome in enterococci. J Antimicrob Chemother 1996;38:751-752.
13. Neu HC, Labthavikul P. In vitro activity of teichomycin compared with those of other antibiotics. Antimicrob Agents Chemother 1983;24:425-428.
14. Tuazon C, Miller H. Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci. Antimicrob Agents Chemother 1984;25:411-412.
15. Leport C, Perronne C, Massip P, Canton P, Leclercq P, Bernard E, et al. Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients. Antimicrob Agents Chemother. 1989;33:879-876.
16. Lewis PJ, Martino P, Mosconi G, Harding I. Teicoplanin in endocarditis: a multicentre, open European study. Chemotherapy 1995;41:399-411.
17. Presterl E, Graninger W, Georgopoulos A. The efficacy of teicoplanin in the treatment of endocarditis caused by gram-positive bacteria. J Antimicrob Chemother. 1993;31:755-766.
18. Wilson APR, Gaya H. Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases. J Antimicrob Chemother. 1996:38:507-521.
19. Venditti M, Tarasi A, Capone A, Galie M, Menichetti F, Martino P, Serra P. Teicoplanin in the treatment of enterococcal endocarditis: clinical and microbiological study. J Antimicrob Chemother 1997:40:449-452.
20. Campoli-Richards DM, Brogden RN, Faulds D. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1990;40:449-486
21. Facklam RR and Collins MD. Identification of Enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol 1989;27:731-734.
22. National Committee for Clinical Laboratory Standards. Development of in vitro susceptibility testing criteria and quality control parameters; Approved guidelines. NCCLS document M23-A. National Committee for Clinical Laboratory Standards, Villanova, PA 1994
23. Perlman BB and Freedman LR. Experimental endocarditis II. Staphylococcal infection of the aortic valve following placement of polyethylene catheter in the left side of the heart. Yale J Biol Med 1971;44:214-224.
24. th ed. American Society for Microbiology, Washington DC, p 1009-1014, 1985.
25. Barry AL, Sabath LD. Special tests: Bactericidal activity and activity of antimicrobials in combination. In Manual of Clinical Microbiology, Ed 2, edited by EH Lenette, EH Spaulding and JP Truant. American Society for Microbiology. Washington, DC, pp.431-435.
26. ao JD, Thauvin-Eliopoulos C, Eliopoulos GM, Moellering RC Jr. Efficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a β-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob Agents Chemother 1990;34:827-830.
27. Chambers HF, Kennedy S. Effects of dosage, peak and trough concentration in serum protein binding, and bactericidal rate of efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother 1990;34:510-514
28. Cremieux AC, Maziere B, Vallois JM, Ottaviani M, Azancot A, Raffoul H, et al. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis 1989;159:938-944.
29. Assandri A, and A Bernareggi. Binding of teicoplanin to human serum albumin. Eur J Pharmacol 1987;33:191-195.
30. Greenwood D. Microbiological properties of teicoplanin. J Antimicrob Chemother 1988;21(Suppl.A):1-13
31. Wilson APR, Grunenberg RN. Use of teicoplanin in community medicine. Europ J Clin Microb Inf Dis. 1994;13:701-10.
32. MacGowan A, White L, Reeves D, Harding I. Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome. J Infect Chemother 1996; 2: 197-208.